Stock Analysis
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis
ACADIA Pharmaceuticals Inc. (ACAD) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
ACADIA Pharmaceuticals Inc. (ACAD) currently has an AIQ Score of 69/100, indicating a neutral setup. Quality is the strongest factor at 92/100. Momentum is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ACAD at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $28.02 |
| AIQ Score | 69/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $4.95B |
| P/E Ratio | 13.01 |
| Forward P/E | — |
| EPS | $0.18 |
| Revenue TTM | $307.96M |
| Dividend Yield | 0.00% |
| Beta | 0.85 |
| Volume | 1.68M |
| 52-week range | $19.69-$30.96 |
| RSI 14 | 43.08 |
| 50-Day SMA | $27.29 |
| 200-Day SMA | $24.47 |
| Analyst Price Target | $33.71 |
| Next Earnings | Nov 4, 2026 |
ACAD
OverviewACAD Stock Analysis Summary
ACADIA Pharmaceuticals Inc. (ACAD) currently has an AIQ Score of 69/100, indicating a neutral setup. Quality is the strongest factor at 92/100. Momentum is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ACAD has AIQ Score of 69/100 with Quality base of 92/100 and fading Momentum at 55/100. Wait for component alignment before adding exposure.
Quality (92/100) leads while Momentum (55/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.57% stock move · ACAD classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ACAD Bullish or Bearish Right Now?
ACAD currently has a neutral overall setup. Quality is the strongest factor at 92/100, while Momentum is weakest at 55/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 92/100.
- - Risk Resilience is supportive at 69/100.
- - Price is +2.69% above its 50-day SMA.
- - Analyst target implies +20.31% upside from the latest quote.
- - Technical consensus has more sell votes than buy votes (24 vs 17).
Current Consensus
ACAD's Technical Analysis Consensus is currently Sell, with 17 buy, 4 neutral, and 24 sell votes. ACAD's 14-day RSI is 43.08, which places the stock in a weaker momentum range. ACAD's beta is 0.85, indicating market sensitivity broadly in line with the market.
What Changed in ACAD?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the ACAD Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ACAD Decision Framework
Public evidence layers, setup checks, and risk context for ACADIA Pharmaceuticals Inc..
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis
ACADIA Pharmaceuticals Inc. has an AIQ Score of 69/100 in a Neutral regime. Quality is strongest at 92/100. Beta is 0.85, below market sensitivity. Review the supporting factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ACAD is in a Neutral AIQ regime with score 69/100. |
| Signal Conflict | The primary conflict is that quality leads at 92/100 while momentum lags at 55/100. |
| Factor Evidence | Momentum 55/100 · Value 57/100 · Quality 92/100 · Risk 69/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 92/100.
Momentum is 55/100 and RSI (14) is 43.1.
ACAD is in a Neutral regime at 69/100.
Risk factor is 69/100 with beta 0.85 and annual volatility 38.04%.
Current conflict: quality leads at 92/100 while momentum lags at 55/100.
ACAD Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ACAD Fundamentals
ACAD valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ACAD Technical Analysis
ACAD technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ACAD Stock Catalysts
Track ACAD earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ACAD Dividend Analysis
ACAD dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ACAD Financial Data
ACAD revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ACAD Risk Analysis
ACAD volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ACAD Stock News
ACAD stock news, market tone, recent headlines, and catalyst context.
ACAD vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: ACAD · ALNY · ARWR · BDTX · BEAM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ACAD Current stock | 69/100 | 57/100 | 55/100 | 69/100 | 0.34 | 38.04% | Current |
| ALNY Alnylam Pharmaceuticals | 62/100 | 26/100 | 88/100 | 45/100 | -0.96 | 47.10% | ACAD vs ALNY |
| ARWR Arrowhead Pharmaceuticals | 42/100 | 34/100 | 55/100 | 58/100 | 2.08 | 61.43% | ACAD vs ARWR |
| BDTX Black Diamond Therapeutics | 41/100 | — | 59/100 | 37/100 | 0.02 | 82.74% | ACAD vs BDTX |
| BEAM Beam Therapeutics | 44/100 | 34/100 | 71/100 | 36/100 | 0.94 | 75.40% | ACAD vs BEAM |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 4, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the stock profit calculator with ticker context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 5, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ACAD
Open the detailed evidence pages and workflows behind the overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ACAD
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ACAD Stock FAQ
What is ACAD stock price today?
ACADIA Pharmaceuticals Inc.'s current stock price is $28.02. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ACAD bullish or bearish right now?
ACAD's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ACAD's market cap?
ACAD's market cap is $4.95B based on the latest completed market-close snapshot from Sep 4, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ACAD's current P/E ratio?
ACAD's current P/E ratio is 13.01 based on the latest completed market-close snapshot from Sep 4, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ACAD's RSI?
ACAD's 14-day RSI is 43.08 based on the latest completed market-close snapshot from Sep 4, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ACAD above its 50-day and 200-day moving averages?
ACAD is 2.69% from its 50-day SMA and 14.53% from its 200-day SMA based on the latest completed market-close snapshot from Sep 4, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ACAD's next earnings date?
ACAD's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ACAD pay a dividend?
ACAD's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 4, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.